Hamlet BioPharma, the pharmaceutical company, specializing in the development of drugs for cancer and infections, today announces the successful first...
Hamlet BioPharma, the pharmaceutical company, specializing in the development of drugs for cancer and infections, today announces progress in Tubercul...
As previously announced Hamlet BioPharma invites you to our monthly investors’ meeting to be held on the 18th of June 2025, at 12:00.
Please click on ...
Med anledning av bolagets kvartalsrapport 3 för 2024/2025, bjuder Hamlet BioPharma in till en livesänd digital pressträff torsdagen den 22 maj, 2025, ...
Som tidigare rapporterats har Hamlet BioPharma uppnått banbrytande forskningsresultat om Alpha1H, bolagets läkemedelskandidat mot urinblåsecancer. I s...
As previously reported, Hamlet BioPharma has achieved a groundbreaking scientific discovery related to Alpha1H, the company’s lead drug candidate for t...
Hamlet BioPharma utvald att presentera framgångsrika prekliniska och kliniska data för Alpha1H vid AACR 2025 vid American Association for Cancer Resea...
As previously announced Hamlet BioPharma invites you to our monthly investors’ meeting to
be held on the 23rd of April 2025, at 12:00.
Please click on...
Hamlet BioPharma, the pharmaceutical company, specializing in the development of drugs
for cancer and infections, announces the publication of new sci...
